<DOC>
	<DOCNO>NCT01005004</DOCNO>
	<brief_summary>The purpose study determine safety preliminary effectiveness human central nervous system stem cell ( HuCNS-SCÂ® ) transplantation patient Connatal Pelizaeus-Merzbacher Disease ( PMD ) .</brief_summary>
	<brief_title>Study Human Central Nervous System ( CNS ) Stem Cells Transplantation Pelizaeus-Merzbacher Disease ( PMD ) Subjects</brief_title>
	<detailed_description>Enrolled subject transplant HuCNS-SC cell brain receive immunosuppression nine month . The study observation period one year transplant surgery . Thereafter , subject enrol long-term observational follow-up study four year .</detailed_description>
	<mesh_term>Pelizaeus-Merzbacher Disease</mesh_term>
	<criteria>Confirmed clinical diagnosis connatal PMD Molecular genetic confirmation mutation proteolipid protein 1 ( PLP1 ) gene MRI consistent PMD interpret qualified neuroradiologist Other significant congenital brain abnormality relate PMD Previous participation gene transfer cell transplant trial Presence neurological sign symptom consistent PMD Current prior malignancy Prior organ , tissue bone marrow transplant</criteria>
	<gender>Male</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>PMD</keyword>
	<keyword>stem cell</keyword>
	<keyword>Pelizaeus-Merzbacher Disease</keyword>
	<keyword>human stem cell</keyword>
	<keyword>central nervous system stem cell</keyword>
</DOC>